Hypomethylating agents for the treatment of myelodysplastic syndromes

被引：4

作者：

Itzykson, Raphael ^{[2
,3
]}

Fenaux, Pierre ^{[1
,3
]}

机构：

[1] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France

[2] Inst Gustave Roussy, INSERM, U1009, F-94805 Villejuif, France

[3] Hop Avicenne, INSERM, U1009, Serv Hematol Clin, F-93009 Bobigny, France

来源：

BULLETIN DU CANCER | 2011年 / 98卷 / 08期

关键词：

myelodysplastic syndromes; hypomethylating agents; azacitidine; decitabine; ACUTE MYELOID-LEUKEMIA; CONVENTIONAL CARE REGIMENS; METHYLATION PREDICTS; CLINICAL-RESPONSE; DNA METHYLATION; AZACITIDINE; DECITABINE; SURVIVAL; CANCER; 5-AZA-2'-DEOXYCYTIDINE;

D O I：

10.1684/bdc.2011.1411

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Azacitidine has been approved in January 2009 in Europe in the treatment of higher-risk myelodysplastic syndromes (MDS). This represents the first time a drug is specifically labelled in MDS in Europe, and is a cornerstone in the development of hypomethylating agents 5-azacytidine (azacitidine) and 5-deoxyazacytidine (decitabine). Clinical trials of hypomethylating agents in MDS still raise a number of questions regarding the precise mode of action of these drugs, as well as the optimal sequencing of treatment in MDS. The positive results of these trials also open the field of epigenetic therapeutic strategies combining hypomethylating agents with other classes of drugs targeting epigenetic processes.

引用

页码：927 / 934

页数：8

共 50 条

[1] Use of Oral Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes
Venugopal, Sangeetha
Garcia-Manero, Guillermo
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S73 - S76
[2] Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia
Szmigielska-Kaplon, Anna
Robak, Tadeusz
[J]. CURRENT CANCER DRUG TARGETS, 2011, 11 (07) : 837 - 848
[3] Venetoclax Combination with Hypomethylating Agents for Treatment of Myelodysplastic Syndromes
Al Ali, Najla
Sallman, David
Nelson, Rebecca
Talati, Chetasi
Kuykendall, Andrew
Sweet, Kendra
Padron, Eric
Lancet, Jeffrey
List, Alan
Komrokji, Rami
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S339 - S340
[4] Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes
Finelli, Carlo
Follo, Matilde Y.
Stanzani, Marta
Parisi, Sarah
Clissa, Cristina
Mongiorgi, Sara
Barraco, Marilena
Cocco, Lucio
[J]. CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (16) : 2349 - 2357
[5] Optimizing hypomethylating agents in myelodysplastic syndromes
Itzykson, Raphael
Fenaux, Pierre
[J]. CURRENT OPINION IN HEMATOLOGY, 2012, 19 (02) : 65 - 70
[6] Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents
Festuccia, Moreno
Baker, Kelsey
Gooley, Theodore A.
Sandmaier, Brenda M.
Deeg, H. Joachim
Scott, Bart L.
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (09) : 1509 - 1514
[7] Hematologic Outcomes of Myelodysplastic Syndromes Treatment With Hypomethylating Agents in Community Practice
Bordoni, Rodolfo E.
Feinberg, Bruce A.
Gilmore, James W.
Haislip, Sally
Jackson, James H.
Farrelly, Eileen
Kim, Edward
Buchner, Deborah
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (04): : 350 - 354
[8] Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Perspectives on Treatment
Zeidan, Amer M.
Jayade, Sayeli
Schmier, Jordana
Botteman, Marc
Hassan, Audrey
Ruiters, Desiree
Hill, Kala
Joshi, Namita
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : E185 - E198
[9] Beyond hypomethylating agents failure in patients with myelodysplastic syndromes
Zeidan, Amer M.
Kharfan-Dabaja, Mohamed A.
Komrokji, Rami S.
[J]. CURRENT OPINION IN HEMATOLOGY, 2014, 21 (02) : 123 - 130
[10] Meta-analysis on hypomethylating agents in myelodysplastic syndromes
Herbst, Christine
Baner, Kathrin
Kreuzer, Karl-Anton
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (02): : 342 - 343

← 1 2 3 4 5 →